CEO received an award of 58K TECH derivative securities | OQRO Insider tradesWhy it stands out
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Aug 17, 2026
- Reporting period
- Not applicable
- Filed with the SEC
- Aug 19, 2026
CEOGrant / award
Context
- Classification
grant award
Code A — grant or award
- Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0000914190-26-000133
- Filed / recorded
Added to OQROOct 2, 2026, 12:27 PM UTC Data qualityVerified: identifiers matched exactly Reporting personKim Kelderman RelationshipDirector, Officer Officer titleChief Executive Officer SecurityRestricted Stock Units TableDerivative (Table II) Transaction dateAug 17, 2026 Acquired / disposedAcquired (A) Footnotes from the filing
- Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- 19,197 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 19,196 restricted stock units vest on 8/17/2029.
Around the same time
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.